Abstract:BACKGROUND AND PURPOSE:Activation of human platelets by thrombin is mediated predominately through two proteinase-activated receptors (PARs), PAR1 and PAR4. Phosphatidylinositol 3-kinase (PI3K) inhibition leads to reversible PAR1-mediated platelet aggregation, but has no effect on the stability of platelet aggregation induced by thrombin. In the present study, the molecular mechanisms underlying this difference were investigated. EXPERIMENTAL APPROACH:The functions of PI3K and PAR4 were assessed using specific inhibitors and aggregometry. The duration of platelet glycoprotein (GP) IIb/IIIa exposure was determined by flow cytometry with the antibody PAC-1. Western blotting and fluo-3 was used to evaluate the activation of Akt and protein kinase C (PKC) and intracellular Ca(2+) mobilization respectively. KEY RESULTS:When PAR4 function was inhibited either by the PAR4 antagonist YD-3 [1-benzyl-3-(ethoxycarbonylphenyl)-indazole] or by receptor desensitization, the PI3K inhibitor wortmannin turned thrombin-elicited platelet aggregation from an irreversible event to a reversible event. Moreover, wortmannin plus YD-3 markedly accelerated the inactivation of GPIIb/IIIa in thrombin-stimulated platelets. The aggregation-reversing activity mainly resulted from inhibition of both PI3K-dependent PKC activation and PAR4-mediated sustained intracellular Ca(2+) rises. Blockade of ADP P2Y(12) receptor with 2-methylthioadenosine 5'-monophosphate triethylammonium salt mimicked the inhibitory effect of wortmannin on PI3K-dependent PKC activation and its ability to reverse PAR1-activating peptide-induced platelet aggregation. Co-administration of 2-methylthioadenosine 5'-monophosphate triethylammonium salt with YD-3 also decreased the stability of thrombin-induced platelet aggregation. CONCLUSIONS AND IMPLICATIONS:These results suggest that PAR4 acts in parallel with the P2Y(12)/PI3K pathway to stabilize platelet aggregates, and provide new insights into the mechanisms of thrombus stabilization and potential applications for antithrombotic therapy.

Mechanism of Action of Protease-Activated Receptors 1 and 4 in Platelet Activation

Modulation of protease-activated receptor expression by Porphyromonas gingivalis in human gingival epithelial cells

Distinct platelet packaging, release, and surface expression of proangiogenic and antiangiogenic factors on different platelet stimuli

Protease-Activated Receptor-2 Simultaneously Directs Beta-Arrestin-1-Dependent Inhibition and G Alpha Q-Dependent Activation of Phosphatidylinositol 3-Kinase

The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation.

Protease-Activated Receptor 4 (PAR4): A Promising Target for Antiplatelet Therapy

The roles and mechanisms of PAR4 and P2Y12-phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation: PAR4 and PI3K stabilize platelet aggregates

The role of PAR4 in thrombin-induced thromboxane production in human platelets.

Platelet Protease-Activated Receptor (PAR)4, but Not PAR1, Associated with Neutral Sphingomyelinase Responsible for Thrombin-Stimulated Ceramide-Nf-κb Signaling in Human Platelets.

[Role of Adenosine Diphosphate in the Course of Thrombin Signal Transmission].

[Role of phosphatidylinositol 3-kinase and myosin light chain kinase during the activation of thrombin receptors].

Role of PI3-K and Mlck during Activation of Thrombin Receptors

A mouse model of the protease-activated receptor 4 Pro310Leu variant has reduced platelet reactivity

[Functions of Thrombin Receptors in the Reversible Distribution of Platelet Surface Glycoprotein I Balpha in Activated Platelets].

Divergent effects of C4a, C4a , and thrombin on platelet aggregation and phosphorylation of ERK and Akt in human endothelial cells

A critical role for the regulation of Syk from agglutination to aggregation in human platelets

Structural Basis for the Activation of Proteinase-Activated Receptors (PARs) by Endogenous Ligands

Role of G Protein–gated Inwardly Rectifying Potassium Channels in P2Y12receptor–mediated Platelet Functional Responses

Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents

Inhibitors of Protease-Activated Receptor 4 (PAR4): a Review of Recent Patents (2013-2021).

Platelet Thrombin Receptors in Maintenance Haemodialysis Patients:Expression and Significance